Articles by Melissa Badamo
The study investigated the role of multi-cancer early detection tests (MCEDs) on patient survival outcomes.
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
SGR-1505 has shown promising efficacy and safety in an ongoing, phase 1 dose-escalation study.
Revumenib has received FDA Priority Review with a Prescription Drug User Fee Act target action date of October 25, 2025.
Tuspetinib plus standard of care venetoclax and azacitidine in newly-diagnosed AML showed promising safety and efficacy.
Paola Ghione, MD, discusses these findings and how breast implant-associated anaplastic large cell lymphoma is managed.
11 of 17 patients who achieved a complete or partial response were able to bridge to HSCT.
Josie Ford, of Mass General Hospital, shared real-world efficacy and safety data on duvelisib and romidepsin in PTCL.
The approval of tafasitamab-cxix in combination with rituximab and lenalidomide was based on the phase 3 inMIND trial.
SENTI-202, a first-in-class, off-the-shelf, logic-gated CAR-NK cell therapy, is currently being evaluated in a phase 1 trial.
Dr. Bhatnagar shared her research interests on rural disparities in AML and her experience working in a community setting.
This issue of Blood Cancers Today includes a feature on AI in oncology, a Get to Know with Bhavana Bhatnagar, DO, and more.
Talquetamab plus teclistamab yields high responses in patients with relapsed/refractory myeloma and extramedullary disease.
The ratio of T cells to neutrophils at the time of leukapheresis was associated with better outcomes, Dr. Voorhees explained.
Isatuximab added to bortezomib, lenalidomide, and dexamethasone showed a significant PFS benefit in myeloma.
At 5 years, 33% of patients with myeloma receiving cilta-cel in the CARTITUDE-1 trial are alive and disease free.
The phase 3 SURPASS-ET trial presented at ASCO evaluated ropeginterferon alfa-2b versus anagrelide for the treatment of ET.
Acalabrutinib plus bendamustine-rituximab is a new standard therapy for patients 65 years or older with untreated MCL.
Of 128 efficacy-evaluable patients, the ORR was 80.5% and the CR rate was 74.2% at a median follow-up of 28.3 months.
Azacitidine plus valproic acid is a safe and feasible maintenance regimen for patients with high-risk AML and MDS after HSCT.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.